Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - quinapril hydrochloride, quantity: 21.664 mg (equivalent: quinapril, qty 20 mg) - tablet, film coated - excipient ingredients: magnesium stearate; colloidal anhydrous silica; povidone; crospovidone; magnesium carbonate hydrate; calcium sulfate dihydrate; titanium dioxide; purified talc; iron oxide yellow; xanthan gum; polyvinyl alcohol; lecithin - hypertension: quinapril hydrochloride tablets are indicated for the treatment of hypertension. it may be used alone or in combination with thiazide diuretics. sufficient data have not been provided to support the use of quinapril tablets in renovascular hypertension. congestive heart failure: quinapril hydrochloride tablets are indicated as an adjunctive treatment of mild to moderate congestive heart failure when given concomitantly with a diuretic and/or cardiac glycoside.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - quinapril hydrochloride, quantity: 10.832 mg (equivalent: quinapril, qty 10 mg) - tablet, film coated - excipient ingredients: calcium sulfate dihydrate; magnesium stearate; magnesium carbonate hydrate; colloidal anhydrous silica; crospovidone; povidone; titanium dioxide; purified talc; iron oxide yellow; xanthan gum; polyvinyl alcohol; lecithin - hypertension: quinapril hydrochloride tablets are indicated for the treatment of hypertension. it may be used alone or in combination with thiazide diuretics. sufficient data have not been provided to support the use of quinapril tablets in renovascular hypertension. congestive heart failure: quinapril hydrochloride tablets are indicated as an adjunctive treatment of mild to moderate congestive heart failure when given concomitantly with a diuretic and/or cardiac glycoside.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - quinapril hydrochloride, quantity: 5.416 mg (equivalent: quinapril, qty 5 mg) - tablet, film coated - excipient ingredients: magnesium stearate; magnesium carbonate hydrate; calcium sulfate dihydrate; povidone; crospovidone; colloidal anhydrous silica; titanium dioxide; xanthan gum; iron oxide yellow; purified talc; polyvinyl alcohol; lecithin - hypertension: quinapril hydrochloride tablets are indicated for the treatment of hypertension. it may be used alone or in combination with thiazide diuretics. sufficient data have not been provided to support the use of quinapril tablets in renovascular hypertension. congestive heart failure: quinapril hydrochloride tablets are indicated as an adjunctive treatment of mild to moderate congestive heart failure when given concomitantly with a diuretic and/or cardiac glycoside.

Evropska unija - angleščina - EMA (European Medicines Agency)

novartis europharm ltd. - amlodipine, valsartan, hydrochlorothiazide - hypertension - angiotensin ii antagonists, plain, angiotensin ii antagonists, combinations - treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of amlodipine, valsartan and hydrochlorothiazide (hct), taken either as three single-component formulations or as a dual-component and a single-component formulation.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - losartan potassium, quantity: 25 mg - tablet, film coated - excipient ingredients: magnesium stearate; pregelatinised maize starch; lactose monohydrate; microcrystalline cellulose; titanium dioxide; hypromellose; hyprolose - hypertension: cozavan is indicated for the treatment of hypertension. it may be used alone or in combination with other antihypertensive agents (e.g. thiazide diuretics). renal protection in type 2 diabetic patients with proteinuria: cozavan is indicated to delay the progression of renal disease in hypertensive type 2 diabetics with proteinuria, defined as urinary albumin to creatinine ratio greater than or equal to 300mg/g.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - losartan potassium, quantity: 50 mg - tablet, film coated - excipient ingredients: lactose monohydrate; pregelatinised maize starch; microcrystalline cellulose; magnesium stearate; titanium dioxide; hypromellose; hyprolose - hypertension: cozavan is indicated for the treatment of hypertension. it may be used alone or in combination with other antihypertensive agents (e.g. thiazide diuretics). renal protection in type 2 diabetic patients with proteinuria: cozavan is indicated to delay the progression of renal disease in hypertensive type 2 diabetics with proteinuria, defined as urinary albumin to creatinine ratio greater than or equal to 300mg/g.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - metoprolol tartrate, quantity: 100 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; crospovidone; colloidal anhydrous silica; microcrystalline cellulose; magnesium stearate; calcium hydrogen phosphate dihydrate; hyprolose - hypertension; angina pectoris; suspected or definite myocardial infarction; migraine prophylaxis.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - metoprolol tartrate, quantity: 50 mg - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; maize starch; calcium hydrogen phosphate dihydrate; lactose monohydrate; crospovidone; hyprolose; magnesium stearate; microcrystalline cellulose - hypertension; angina pectoris; suspected or definite myocardial infarction; migraine prophylaxis

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - metoprolol tartrate, quantity: 100 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; crospovidone; colloidal anhydrous silica; microcrystalline cellulose; magnesium stearate; calcium hydrogen phosphate dihydrate; hyprolose - hypertension; angina pectoris; suspected or definite myocardial infarction; migraine prophylaxis.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - metoprolol tartrate, quantity: 50 mg - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; maize starch; calcium hydrogen phosphate dihydrate; lactose monohydrate; crospovidone; hyprolose; magnesium stearate; microcrystalline cellulose - hypertension; angina pectoris; suspected or definite myocardial infarction; migraine prophylaxis